2024-01-22 13:17:30 ET
Summary
- Today, we take a deeper look at Sage Therapeutics, Inc., a biopharmaceutical company focused on developing brain health medicines.
- The stock has fallen sharply since June on a more limited FDA approval for the company's primary drug candidate.
- The drug has just been launched and management has taken actions to substantially lower annual operating costs.
- What's ahead for Sage Therapeutics in 2024? An analysis follows in the paragraphs below.
We cannot change the cards we are dealt, just how we play the hand .” ? Randy Pausch.
Read the full article on Seeking Alpha
For further details see:
Sizing Up Sage Therapeutics